Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|October 23, 2020
Dangerous CV Drug-Drug Interactions: A 5-question Quiz
Author(s)Alex Evans, PharmD, MBA
Cardiovascular medications are widely-prescribed in the US. Alex Evans, PharmD, MBA, drafted questions on the top 5 dangerous interactions he sees regularly in practice.
Advertisement
Medications for cardiovascular disease dominate the list of
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement
Trending on Patient Care Online
1
Evolocumab Tied to 20% Lower Risk of Myocardial Infarction vs Ezetimibe in Real-World Study
2
FDA Clears 15-Minute Blood Test to Help Distinguish Bacterial From Viral Infections
3
One Question PCPs Should Ask Every Patient with Atrial Fibrillation
4
4 FDA Decisions for Primary Care to Know from October 2026
5